
Novo Nordisk A/S (NYSE: NVO) Stock Competitors & Peer Comparison
See NVO's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Drug Manufacturers - General Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for NVO and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| NVO | $41.63 | +2.41% | 184.5B | 10.36 | $4.02 | +4.31% |
| LLY | $1,443.50 | +1.26% | 1.4T | 45.90 | $31.49 | +0.48% |
| JNJ | $285.75 | +0.79% | 688.8B | 26.66 | $10.73 | +1.84% |
| ABBV | $295.03 | +0.20% | 521.6B | 28.96 | $10.19 | +2.34% |
| MRK | $147.76 | +0.55% | 364.3B | 46.03 | $3.21 | +2.30% |
| NVS | $160.50 | +0.16% | 303.2B | 18.47 | $8.69 | +2.95% |
| AZN | $184.45 | +0.04% | 286.1B | 19.92 | $9.26 | +1.75% |
| AMGN | $465.67 | -0.30% | 251.9B | 20.82 | $22.37 | +2.13% |
| GILD | $168.08 | +0.08% | 208.5B | -430.97 | -$0.39 | +1.93% |
| PFE | $28.89 | +0.21% | 164.7B | 9.47 | $3.05 | +5.96% |
Stock Comparison
Eli Lilly and Company (NYSE: LLY)
NVO vs LLY Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, LLY has a market cap of 1.4T. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while LLY trades at $1,443.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas LLY's P/E ratio is 45.90. In terms of profitability, NVO's ROE is +0.54%, compared to LLY's ROE of +0.84%. Regarding short-term risk, NVO is more volatile compared to LLY. This indicates higher risk in terms of short-term price fluctuations for NVO.Check LLY's competition here
Johnson & Johnson (NYSE: JNJ)
NVO vs JNJ Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, JNJ has a market cap of 688.8B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while JNJ trades at $285.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas JNJ's P/E ratio is 26.66. In terms of profitability, NVO's ROE is +0.54%, compared to JNJ's ROE of +0.20%. Regarding short-term risk, NVO is more volatile compared to JNJ. This indicates higher risk in terms of short-term price fluctuations for NVO.Check JNJ's competition here
AbbVie Inc. (NYSE: ABBV)
NVO vs ABBV Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, ABBV has a market cap of 521.6B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while ABBV trades at $295.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas ABBV's P/E ratio is 28.96. In terms of profitability, NVO's ROE is +0.54%, compared to ABBV's ROE of -2.02%. Regarding short-term risk, NVO is more volatile compared to ABBV. This indicates higher risk in terms of short-term price fluctuations for NVO.Check ABBV's competition here
Merck & Co., Inc. (NYSE: MRK)
NVO vs MRK Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, MRK has a market cap of 364.3B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while MRK trades at $147.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas MRK's P/E ratio is 46.03. In terms of profitability, NVO's ROE is +0.54%, compared to MRK's ROE of +0.05%. Regarding short-term risk, NVO is more volatile compared to MRK. This indicates higher risk in terms of short-term price fluctuations for NVO.Check MRK's competition here
Novartis AG (NYSE: NVS)
NVO vs NVS Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, NVS has a market cap of 303.2B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while NVS trades at $160.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas NVS's P/E ratio is 18.47. In terms of profitability, NVO's ROE is +0.54%, compared to NVS's ROE of +0.25%. Regarding short-term risk, NVO is more volatile compared to NVS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check NVS's competition here
AstraZeneca PLC (NYSE: AZN)
NVO vs AZN Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, AZN has a market cap of 286.1B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while AZN trades at $184.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas AZN's P/E ratio is 19.92. In terms of profitability, NVO's ROE is +0.54%, compared to AZN's ROE of +0.22%. Regarding short-term risk, NVO is more volatile compared to AZN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check AZN's competition here
Amgen Inc. (NASDAQ: AMGN)
NVO vs AMGN Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, AMGN has a market cap of 251.9B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while AMGN trades at $465.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas AMGN's P/E ratio is 20.82. In terms of profitability, NVO's ROE is +0.54%, compared to AMGN's ROE of +0.86%. Regarding short-term risk, NVO is more volatile compared to AMGN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check AMGN's competition here
Gilead Sciences, Inc. (NASDAQ: GILD)
NVO vs GILD Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, GILD has a market cap of 208.5B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while GILD trades at $168.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas GILD's P/E ratio is -430.97. In terms of profitability, NVO's ROE is +0.54%, compared to GILD's ROE of -0.22%. Regarding short-term risk, NVO is more volatile compared to GILD. This indicates higher risk in terms of short-term price fluctuations for NVO.Check GILD's competition here
Pfizer Inc. (NYSE: PFE)
NVO vs PFE Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, PFE has a market cap of 164.7B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while PFE trades at $28.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas PFE's P/E ratio is 9.47. In terms of profitability, NVO's ROE is +0.54%, compared to PFE's ROE of +0.05%. Regarding short-term risk, NVO is more volatile compared to PFE. This indicates higher risk in terms of short-term price fluctuations for NVO.Check PFE's competition here
Bristol-Myers Squibb Company Ce (NYSE: CELG-RI)
NVO vs CELG-RI Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, CELG-RI has a market cap of 136.4B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while CELG-RI trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas CELG-RI's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.54%, compared to CELG-RI's ROE of +0.44%. Regarding short-term risk, NVO is less volatile compared to CELG-RI. This indicates lower risk in terms of short-term price fluctuations for NVO.Check CELG-RI's competition here
Bristol-Myers Squibb Company (NYSE: BMY)
NVO vs BMY Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, BMY has a market cap of 129.6B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while BMY trades at $63.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas BMY's P/E ratio is 10.69. In terms of profitability, NVO's ROE is +0.54%, compared to BMY's ROE of +0.44%. Regarding short-term risk, NVO is less volatile compared to BMY. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BMY's competition here
Sanofi (NASDAQ: SNY)
NVO vs SNY Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, SNY has a market cap of 115.9B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while SNY trades at $48.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas SNY's P/E ratio is 10.54. In terms of profitability, NVO's ROE is +0.54%, compared to SNY's ROE of +0.06%. Regarding short-term risk, NVO is more volatile compared to SNY. This indicates higher risk in terms of short-term price fluctuations for NVO.Check SNY's competition here
GSK plc (NYSE: GSK)
NVO vs GSK Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, GSK has a market cap of 102.2B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while GSK trades at $50.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas GSK's P/E ratio is 10.90. In terms of profitability, NVO's ROE is +0.54%, compared to GSK's ROE of +0.23%. Regarding short-term risk, NVO is more volatile compared to GSK. This indicates higher risk in terms of short-term price fluctuations for NVO.Check GSK's competition here
Biogen Inc. (NASDAQ: BIIB)
NVO vs BIIB Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, BIIB has a market cap of 37.5B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while BIIB trades at $253.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas BIIB's P/E ratio is 16.00. In terms of profitability, NVO's ROE is +0.54%, compared to BIIB's ROE of +0.02%. Regarding short-term risk, NVO is more volatile compared to BIIB. This indicates higher risk in terms of short-term price fluctuations for NVO.Check BIIB's competition here
Horizon Therapeutics Public Limited Company (NASDAQ: HZNP)
NVO vs HZNP Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, HZNP has a market cap of 26.6B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while HZNP trades at $116.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas HZNP's P/E ratio is 61.86. In terms of profitability, NVO's ROE is +0.54%, compared to HZNP's ROE of +0.11%. Regarding short-term risk, NVO is more volatile compared to HZNP. This indicates higher risk in terms of short-term price fluctuations for NVO.Check HZNP's competition here
Grifols, S.A. (NASDAQ: GRFS)
NVO vs GRFS Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, GRFS has a market cap of 7.4B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while GRFS trades at $8.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas GRFS's P/E ratio is 9.98. In terms of profitability, NVO's ROE is +0.54%, compared to GRFS's ROE of +0.09%. Regarding short-term risk, NVO is more volatile compared to GRFS. This indicates higher risk in terms of short-term price fluctuations for NVO.Check GRFS's competition here
Organon & Co. (NYSE: OGN)
NVO vs OGN Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, OGN has a market cap of 3.7B. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while OGN trades at $13.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas OGN's P/E ratio is 4.15. In terms of profitability, NVO's ROE is +0.54%, compared to OGN's ROE of +0.22%. Regarding short-term risk, NVO is more volatile compared to OGN. This indicates higher risk in terms of short-term price fluctuations for NVO.Check OGN's competition here
Amarin Corporation plc (NASDAQ: AMRN)
NVO vs AMRN Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, AMRN has a market cap of 235.4M. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while AMRN trades at $11.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas AMRN's P/E ratio is -113.80. In terms of profitability, NVO's ROE is +0.54%, compared to AMRN's ROE of -0.04%. Regarding short-term risk, NVO is less volatile compared to AMRN. This indicates lower risk in terms of short-term price fluctuations for NVO.Check AMRN's competition here
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA)
NVO vs MIRA Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, MIRA has a market cap of 27.7M. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while MIRA trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas MIRA's P/E ratio is -0.46. In terms of profitability, NVO's ROE is +0.54%, compared to MIRA's ROE of -1.07%. Regarding short-term risk, NVO is less volatile compared to MIRA. This indicates lower risk in terms of short-term price fluctuations for NVO.Check MIRA's competition here
Scilex Holding Company (NASDAQ: SCLX)
NVO vs SCLX Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, SCLX has a market cap of 10.1M. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while SCLX trades at $1.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas SCLX's P/E ratio is -0.04. In terms of profitability, NVO's ROE is +0.54%, compared to SCLX's ROE of +1.90%. Regarding short-term risk, NVO is less volatile compared to SCLX. This indicates lower risk in terms of short-term price fluctuations for NVO.Check SCLX's competition here
Scilex Holding Company (NASDAQ: SCLXW)
NVO vs SCLXW Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, SCLXW has a market cap of 7.8M. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while SCLXW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas SCLXW's P/E ratio is N/A. In terms of profitability, NVO's ROE is +0.54%, compared to SCLXW's ROE of +1.90%. Regarding short-term risk, NVO is more volatile compared to SCLXW. This indicates higher risk in terms of short-term price fluctuations for NVO.Check SCLXW's competition here
BioDelivery Sciences Intl, Inc. Wrrt (NASDAQ: BDSIW)
NVO vs BDSIW Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, BDSIW has a market cap of 0. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while BDSIW trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas BDSIW's P/E ratio is -0.43. In terms of profitability, NVO's ROE is +0.54%, compared to BDSIW's ROE of +0.57%. Regarding short-term risk, NVO is less volatile compared to BDSIW. This indicates lower risk in terms of short-term price fluctuations for NVO.Check BDSIW's competition here
Clarus Therapeutics Holdings, Inc. (NASDAQ: CRXT)
NVO vs CRXT Comparison November 2026
Novo Nordisk A/S (NYSE: NVO) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, NVO stands at 184.5B. In comparison, CRXT has a market cap of 0. Regarding current trading prices, NVO is priced at $41.63 on the NYSE, while CRXT trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
NVO currently has a P/E ratio of 10.36, whereas CRXT's P/E ratio is -0.02. In terms of profitability, NVO's ROE is +0.54%, compared to CRXT's ROE of -4.63%. Regarding short-term risk, NVO is less volatile compared to CRXT. This indicates lower risk in terms of short-term price fluctuations for NVO.Check CRXT's competition here